Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 6/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20764475 | 1.00 | MITF (0.43) | MITFHDAC3NCOR2HDAC1HDAC2 | |
| SCHEMBL22076696 | 0.93 | MMP2 (0.38) | HDAC3NCOR2HDAC1HDAC2NPC1 | |
| SCHEMBL22076698 | 0.93 | MMP2 (0.38) | HDAC3NCOR2HDAC1HDAC2NPC1 | |
| SCHEMBL20764481 | 0.93 | MEN1 (0.44) | HDAC3NCOR2HDAC1HDAC2NPC1 | |
| SCHEMBL20764482 | 0.93 | MEN1 (0.44) | HDAC3NCOR2HDAC1HDAC2NPC1 | |
| SCHEMBL20764477 | 0.92 | MEN1 (0.37) | HDAC3NCOR2HDAC1HDAC2NPC1 | |
| SCHEMBL20764599 | 0.92 | CACNA1B (0.37) | HDAC3NCOR2HDAC1HDAC2MMP2 | |
| SCHEMBL20764473 | 0.92 | MEN1 (0.37) | HDAC3NCOR2HDAC1HDAC2NPC1 | |
| SCHEMBL20764600 | 0.92 | CACNA1B (0.37) | HDAC3NCOR2HDAC1HDAC2MMP2 | |
| SCHEMBL20764571 | 0.92 | P2RY14 (0.39) | NPC1RAB9AMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034648-B2 | Cystobactamide derivatives | HELMHOLTZ-ZENTRUM FÜR (DE) | 2021-06-15 | — | — | US | disclosed |
| EP-3672937-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2020-07-01 | — | — | EP | disclosed |
| US-20200190020-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2020-06-18 | — | — | US | disclosed |
| CN-110997627-A | Novel cystobacter amide derivatives | 亥姆霍兹感染研究中心有限公司 | 2020-04-10 | — | — | CN | disclosed |
| WO-2019038405-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034648-B2 | Cystobactamide derivatives | CTH, CBS, SLC7A11 | MITF 4594/4885HDAC3 3912/4885NCOR2 2982/4885 |
| US-20200190020-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | CTH, CBS, SLC7A11 | MITF 4474/4885HDAC3 3764/4885NCOR2 3191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.